Boundless Bio, Inc. (BOLD) stock
BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $54.82MP/E –Yield –
Boundless Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Boundless Bio's operating income for the twelve months ending Jun 30, 2026 was -$68.01M. For fiscal 2025 it was -$63.55M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$63.55M | – |
| FY2024 | Dec 31, 2024 | -$73.27M | – |
| FY2023 | Dec 31, 2023 | -$54.80M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.48M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.15M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.72M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.95M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.09M | – |
See a number that looks wrong?